This study analyzed the effects of combination therapy with sodium-glucose transporter-2 inhibitors (SGLT2is) and metformin on fracture risk. Summarizing available randomized controlled trials, we found that SGLT2is combined with metformin therapy did not influence fracture risk compared with metformin monotherapy or other comparators in patients with T2DM.
No study is available evaluating the association between sodium-glucose transporter-2 inhibitors (SGLT2is) in combination with metformin use and fracture risk. Our study aimed to investigate the fracture risk of combination therapy with SGLT2is and metformin in patients with type 2 diabetes mellitus (T2DM).
PubMed, Embase, ClinicalTrials.gov site, and the Cochrane Library databases were scrutinized for all eligible randomized controlled trials (RCTs). The summarized odds ratios (ORs) and their 95% confidence intervals (CI) were calculated using Review Manager 5.3 software.
A total of 25 RCTs involving 19,500 participants with T2DM were included in our studies. There were 88 fracture cases in the SGLT2is in combination with metformin therapy group and 79 in the control group. SGLT2is combined with metformin use did not influence fracture risk compared with metformin monotherapy or other comparators in patients with T2DM (OR = 0.97, 95% CI 0.71–1.32). After stratification by drug type, follow-up time, control regimen, and type of fracture, the upshots were still stable.
SGLT2is and metformin combination therapy did not influence fracture risk compared with metformin monotherapy or other comparators in patients with T2DM.
Prospero registration number
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9th edition. Diabetes Res Clin Pract 157:107843. https://doi.org/10.1016/j.diabres.2019.107843
Ma L, Oei L, Jiang L, Estrada K, Chen H, Wang Z, Yu Q, Zillikens MC, Gao X, Rivadeneira F (2012) Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol 27:319–332. https://doi.org/10.1007/s10654-012-9674-x
Mitchell A, Fall T, Melhus H, Wolk A, Michaëlsson K, Byberg L (2018) Type 2 diabetes in relation to hip bone density, area, and bone turnover in Swedish men and women: a cross-sectional study. Calcif Tissue Int 103:501–511. https://doi.org/10.1007/s00223-018-0446-9
Napoli N, Chandran M, Pierroz DD et al (2017) Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol 13:208–219. https://doi.org/10.1038/nrendo.2016.153
Bucala R, Vlassara H (1995) Advanced glycosylation end products in diabetic renal and vascular disease. Am J Kidney Dis 26:875–888. https://doi.org/10.1016/0272-6386(95)90051-9
Chen H-H, Horng M-H, Yeh S-Y, Lin IC, Yeh CJ, Muo CH, Sung FC, Kao CH (2015) Glycemic control with thiazolidinedione is associated with fracture of T2DM patients. PLoS One 10:e0135530. https://doi.org/10.1371/journal.pone.0135530
Zhang Y, Chen Q, Liang Y, Dong Y, Mo X, Zhang L, Zhang B (2019) Insulin use and fracture risk in patients with type 2 diabetes: a meta-analysis of 138,690 patients. Exp Ther Med 17:3957–3964. https://doi.org/10.3892/etm.2019.7461
Zhang Z, Cao Y, Tao Y, E M, Tang J, Liu Y, Li F (2019) Sulfonylurea and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Res Clin Pract 159:107990. https://doi.org/10.1016/j.diabres.2019.107990
Schwartz AV (2017) Diabetes, bone and glucose-lowering agents: clinical outcomes. Diabetologia 60:1170–1179. https://doi.org/10.1007/s00125-017-4283-6
Zhang YS, Weng WY, Xie BC, Meng Y, Hao YH, Liang YM, Zhou ZK (2018) Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials. Osteoporos Int 29:2639–2644. https://doi.org/10.1007/s00198-018-4649-8
Bahrambeigi S, Yousefi B, Rahimi M, Shafiei-Irannejad V (2019) Metformin; an old antidiabetic drug with new potentials in bone disorders. Biomed Pharmacother 109:1593–1601. https://doi.org/10.1016/j.biopha.2018.11.032
Salari-Moghaddam A, Sadeghi O, Keshteli AH, Larijani B, Esmaillzadeh A (2019) Metformin use and risk of fracture: a systematic review and meta-analysis of observational studies. Osteoporos Int 30:1167–1173. https://doi.org/10.1007/s00198-019-04948-1
American Diabetes Association (2020) 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care 43:S98–S110. https://doi.org/10.2337/dc20-S009
Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393:31–39. https://doi.org/10.1016/S0140-6736(18)32590-X
Kuchay MS, Farooqui KJ, Mishra SK, Mithal A (2020) Glucose lowering efficacy and pleiotropic effects of sodium-glucose cotransporter 2 inhibitors. Adv Exp Med Biol. https://doi.org/10.1007/5584_2020_479
Buse JB, Wexler DJ, Tsapas A et al (2020) 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 43:487–493. https://doi.org/10.2337/dci19-0066
Taylor SI, Blau JE, Rother KI (2015) Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol 3:8–10. https://doi.org/10.1016/S2213-8587(14)70227-X
Bilezikian JP, Watts NB, Usiskin K, Polidori D, Fung A, Sullivan D, Rosenthal N (2016) Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J Clin Endocrinol Metab 101:44–51. https://doi.org/10.1210/jc.2015-1860
Thrailkill KM, Bunn RC, Nyman JS, Rettiganti MR, Cockrell GE, Wahl EC, Uppuganti S, Lumpkin CK Jr, Fowlkes JL (2017) Corrigendum to “SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice” [Bone 82 (2016) 101-107]. Bone 105:316. https://doi.org/10.1016/j.bone.2016.11.021
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657. https://doi.org/10.1056/NEJMoa1611925
Kohan DE, Fioretto P, Tang W, List JF (2014) Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85:962–971. https://doi.org/10.1038/ki.2013.356
Gallo S, Charbonnel B, Goldman A, Shi H, Huyck S, Darekar A, Lauring B, Terra SG (2019) Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial. Diabetes Obes Metab 21:1027–1036. https://doi.org/10.1111/dom.13631
Bolinder J, Ljunggren Ö, Johansson L, Wilding J, Langkilde AM, Sjöström CD, Sugg J, Parikh S (2014) Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 16:159–169. https://doi.org/10.1111/dom.12189
Lu C-H, Min KW, Chuang L-M, Kokubo S, Yoshida S, Cha BS (2016) Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial. J Diabetes Investig 7:366–373. https://doi.org/10.1111/jdi.12422
Yang W, Han P, Min K-W, Wang B, Mansfield T, T'Joen C, Iqbal N, Johnsson E, Ptaszynska A (2016) Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: a randomized controlled trial. J Diabetes 8:796–808. https://doi.org/10.1111/1753-0407.12357
Lee SY, Park MS, Kwon S-S, Sung KH, Jung HS, Lee KM (2016) Influence of ankle fracture surgery on glycemic control in patients with diabetes. BMC Musculoskelet Disord 17:137. https://doi.org/10.1186/s12891-016-0987-x
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295–2306. https://doi.org/10.1056/NEJMoa1811744
Watts NB, Bilezikian JP, Usiskin K, Edwards R, Desai M, Law G, Meininger G (2016) Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 101:157–166. https://doi.org/10.1210/jc.2015-3167
Zhou Z, Jardine M, Perkovic V, Matthews DR, Mahaffey KW, de Zeeuw D, Fulcher G, Desai M, Oh R, Simpson R, Watts NB, Neal B (2019) Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS program. Diabetologia 62:1854–1867. https://doi.org/10.1007/s00125-019-4955-5
Blau JE, Bauman V, Conway EM, Piaggi P, Walter MF, Wright EC, Bernstein S, Courville AB, Collins MT, Rother KI, Taylor SI (2018) Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study. JCI Insight 3:e99123. https://doi.org/10.1172/jci.insight.99123
Ayus JC, Negri AL, Kalantar-Zadeh K, Moritz ML (2012) Is chronic hyponatremia a novel risk factor for hip fracture in the elderly? Nephrol Dial Transplant 27:3725–3731. https://doi.org/10.1093/ndt/gfs412
Lee PC, Ganguly S, Goh S-Y (2018) Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms. Obes Rev 19:1630–1641. https://doi.org/10.1111/obr.12755
Shapses SA, Riedt CS (2006) Bone, body weight, and weight reduction: what are the concerns? J Nutr 136:1453–1456. https://doi.org/10.1093/jn/136.6.1453
Ruanpeng D, Ungprasert P, Sangtian J, Harindhanavudhi T (2017) Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Metab Res Rev 33. https://doi.org/10.1002/dmrr.2903
Tang HL, Li DD, Zhang JJ, Hsu YH, Wang TS, Zhai SD, Song YQ (2016) Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab 18:1199–1206. https://doi.org/10.1111/dom.12742
Li X, Li T, Cheng Y, Lu Y, Xue M, Xu L, Liu X, Yu X, Sun B, Chen L (2019) Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: an updated meta-analysis. Diabetes Metab Res Rev 35:e3170. https://doi.org/10.1002/dmrr.3170
Azharuddin M, Adil M, Ghosh P, Sharma M (2018) Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: a systematic literature review and Bayesian network meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 146:180–190. https://doi.org/10.1016/j.diabres.2018.10.019
Cheng L, Li Y-Y, Hu W, Bai F, Hao HR, Yu WN, Mao XM (2019) Risk of bone fracture associated with sodium-glucose cotransporter-2 inhibitor treatment: a meta-analysis of randomized controlled trials. Diabetes Metab 45:436–445. https://doi.org/10.1016/j.diabet.2019.01.010
Schmedt N, Andersohn F, Walker J, Garbe E (2019) Sodium-glucose co-transporter-2 inhibitors and the risk of fractures of the upper or lower limbs in patients with type 2 diabetes: a nested case-control study. Diabetes Obes Metab 21:52–60. https://doi.org/10.1111/dom.13480
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128. https://doi.org/10.1056/NEJMoa1504720
Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, Bakker RA, Mark M, Klein T, Eickelmann P (2012) Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14:83–90. https://doi.org/10.1111/j.1463-1326.2011.01517.x
Thrailkill KM, Nyman JS, Bunn RC, Uppuganti S, Thompson KL, Lumpkin CK Jr, Kalaitzoglou E, Fowlkes JL (2017) The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes. Bone 94:141–151. https://doi.org/10.1016/j.bone.2016.10.026
Conflict of interest
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Supplemental Table 1
(DOCX 21 kb).
Supplemental Fig. 1
(PDF 157 kb).
Supplemental Fig. 2
(PDF 3285 kb).
Supplemental Fig. 3
(PDF 6758 kb).
Supplemental Fig. 4
(PDF 5895 kb).
Supplemental Fig. 5
(PDF 3126 kb).
Supplemental Fig. 6
(PDF 1935 kb).
Rights and permissions
About this article
Cite this article
Qian, BB., Chen, Q., Li, L. et al. Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials. Osteoporos Int 31, 2313–2320 (2020). https://doi.org/10.1007/s00198-020-05590-y
- Type 2 diabetes mellitus
- SGLT2 inhibitor